These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9873790)

  • 1. How do some haemophiliacs develop inhibitors?
    Vermylen J
    Haemophilia; 1998 Jul; 4(4):538-42. PubMed ID: 9873790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII.
    Oldenburg J; Ivaskevicius V; Schröder J; Müller CR; Ganguly A
    Thromb Haemost; 2006 May; 95(5):903-5. PubMed ID: 16676088
    [No Abstract]   [Full Text] [Related]  

  • 3. The genetic basis of inhibitor development in haemophilia A.
    Tuddenham EG; McVey JH
    Haemophilia; 1998 Jul; 4(4):543-5. PubMed ID: 9873791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study.
    Jardim LL; van der Bom J; Brommonschenkel CC; Gouw SC; Rezende SM;
    Br J Haematol; 2019 Jul; 186(1):152-155. PubMed ID: 30556277
    [No Abstract]   [Full Text] [Related]  

  • 5. The management of haemophiliacs who have antibodies to factor VIII.
    Rizza CR
    Scand J Haematol Suppl; 1984; 40():187-93. PubMed ID: 6433451
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibitor development in one patient and laboratory discrepancies in several families with both mild haemophilia and Arg531Cys mutation.
    Cid AR; Casaña P; Cabrera N; Haya S; Cortina V; Aznar JA
    Haemophilia; 2007 Mar; 13(2):206-8. PubMed ID: 17286776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E; Zerbinati P; Girolami B; Bertomoro A; Girolami A
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies.
    Brackmann HH; Lenk H; Scharrer I; Auerswald G; Kreuz W
    Haemophilia; 1999 May; 5(3):203-6. PubMed ID: 10444288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.
    Ivaskevicius V; Goldmann G; Horneff S; Marquardt N; Klein C; Albert T; Zeitler H; Oldenburg J
    Hamostaseologie; 2014; 34 Suppl 1():S9-12. PubMed ID: 25382774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 12. Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
    Rommel F; Toepfer M; Eberle J; Schiffl H; Spannagl M; Schramm W
    Thromb Haemost; 2000 Oct; 84(4):733-4. PubMed ID: 11057884
    [No Abstract]   [Full Text] [Related]  

  • 13. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
    Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
    Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor VIII clotting antigen (VIIICAg) in haemophilia measured by two immunoradiometric assays (IRMA) using different antibodies, and the measurement of inhibitors to procoagulant factor VIII (VIIIC) by IRMA.
    Furlong RA; Peake IR; Bloom AL
    Br J Haematol; 1981 Aug; 48(4):643-50. PubMed ID: 6791678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII inhibitors in mild and moderate-severity haemophilia A.
    Hay CR
    Haemophilia; 1998 Jul; 4(4):558-63. PubMed ID: 9873794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 18. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 19. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.
    van Helden PM; Kaijen PH; Mauser-Bunschoten EP; Fischer K; van den Berg HM; Voorberg J
    Haemophilia; 2010 Nov; 16(6):892-901. PubMed ID: 20491952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.
    Martin PG; Sukhu K; Chambers E; Giangrande PL
    Clin Lab Haematol; 1999 Apr; 21(2):125-8. PubMed ID: 10342072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.